Dept. of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, U.S.A..
Dept. of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, U.S.A.
Reprod Biol Endocrinol. 2023 Feb 4;21(1):19. doi: 10.1186/s12958-023-01066-w.
While anti-Müllerian hormone (AMH) predicts quantitative IVF outcomes such as oocyte yield, it is not certain whether AMH predicts markers of oocyte quality such as aneuploidy.
Retrospective case-control analysis of the SART-CORS database, 2014-2016, to determine whether anti-Müllerian hormone (AMH) predicts aneuploidy and live birth in IVF cycles utilizing preimplantation genetic testing for aneuploidy (PGT-A).
Of 51,273 cycles utilizing PGT-A for all embryos, 10,878 cycles were included in the final analysis; of these, 2,100 cycles resulted in canceled transfer due to lack of normal embryos and 8,778 cycles resulted in primary FET. AMH levels of cycles with ≥ 1 euploid embryo were greater than those of cycles with no normal embryos, stratifying by number of embryos biopsied (1-2, 3-4, 5-6, and ≥ 7), P < 0.017 for each stratum. Adjusting for age and number of embryos biopsied, AMH was a significant independent predictor of ≥ 1 euploid embryo for all age groups: < 35 yrs (aOR 1.074; 95%CI 1.005-1.163), 35-37 years (aOR 1.085; 95%CI 1.018-1.165) and ≥ 38 years (aOR 1.055; 95%CI 1.020-1.093). In comparative model analysis, AMH was superior to age as a predictor of ≥ 1 euploid embryo for age groups < 35 years and 35-37 years, but not ≥ 38 years. Across all cycles, age (aOR 0.945, 95% CI 0.935-0.956) and number of embryos (aOR 1.144, 95%CI 1.127-1.162) were associated with live birth per transfer, but AMH was not (aOR 0.995, 95%CI 0.983-1.008). In the subset of cycles resulting in ≥ 1 euploid embryo for transfer, neither age nor AMH were associated with live birth.
Adjusting for age and number of embryos biopsied, AMH independently predicted likelihood of obtaining ≥ 1 euploid embryo for transfer in IVF PGT-A cycles. However, neither age nor AMH were predictive of live birth once a euploid embryo was identified by PGT-A for transfer. This analysis suggests a predictive role of AMH for oocyte quality (aneuploidy risk), but not live birth per transfer once a euploid embryo is identified following PGT-A.
抗苗勒管激素(AMH)可预测卵母细胞数量等定量 IVF 结局,但尚不确定 AMH 是否可预测卵母细胞质量标志物,如非整倍体。
回顾性病例对照分析 2014 年至 2016 年 SART-CORS 数据库,以确定抗苗勒管激素(AMH)是否可预测使用植入前遗传学检测非整倍体(PGT-A)的 IVF 周期中的非整倍体和活产。
在利用 PGT-A 对所有胚胎进行的 51273 个周期中,有 10878 个周期被纳入最终分析;其中,由于缺乏正常胚胎,2100 个周期取消了移植,8778 个周期进行了原发性 FET。活检胚胎数为 1-2、3-4、5-6 和≥7 个时,有≥1 个整倍体胚胎的周期 AMH 水平高于无正常胚胎的周期,P<0.017。调整年龄和活检胚胎数后,AMH 是所有年龄组获得≥1 个整倍体胚胎的独立显著预测因子:<35 岁(优势比 1.074;95%CI 1.005-1.163)、35-37 岁(优势比 1.085;95%CI 1.018-1.165)和≥38 岁(优势比 1.055;95%CI 1.020-1.093)。在比较模型分析中,AMH 在预测年龄<35 岁和 35-37 岁年龄组的≥1 个整倍体胚胎方面优于年龄,而在≥38 岁年龄组则不然。在所有周期中,年龄(优势比 0.945,95%CI 0.935-0.956)和胚胎数(优势比 1.144,95%CI 1.127-1.162)与每周期活产相关,但 AMH 无相关性(优势比 0.995,95%CI 0.983-1.008)。在进行≥1 个整倍体胚胎转移的周期亚组中,年龄和 AMH 均与活产无关。
调整年龄和活检胚胎数后,AMH 独立预测了 IVF PGT-A 周期中获得≥1 个整倍体胚胎的可能性。然而,一旦通过 PGT-A 确定了整倍体胚胎,年龄和 AMH 均与活产无关。这项分析表明 AMH 对卵母细胞质量(非整倍体风险)有预测作用,但在 PGT-A 确定整倍体胚胎后,每周期活产并无预测作用。